Longer leukocyte telomere length is associated with lower markers of early Alzheimer's disease pathology, astrocytic reactivity, and synaptic dysfunction.

Blanca Rodríguez‐Fernández, Armand González Escalante, Patricia Genius, Paula Ortiz‐Romero, Ann Brinkmalm, Carolina Minguillón, Gwendlyn Kollmorgen, Clara Quijano‐Rubio, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Juan Domingo Gispert, Arcadi Navarro, Marc Suarez‐Calvet, Marta Crous‐Bou, Natalia Vilor‐Tejedor

Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, SpainBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain · pubmed

Paper

Abstract

Leukocyte telomere length (LTL) serves as a proxy for tissue‐specific TL and peripheral immune aging. Its association with aging‐related brain endophenotypes, cognitive functioning, and Alzheimer's disease (AD) risk is established, but the underlying molecular mechanisms remain elusive. Investigating LTL's association with AD biomarkers is crucial for identifying its role in brain resilience and disease progression.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the association between leukocyte telomere length and early Alzheimer's disease pathology, which touches on aging-related mechanisms. However, it primarily focuses on correlational findings rather than addressing the root causes of aging or proposing interventions for lifespan extension. The impact is limited as it contributes to understanding biomarkers rather than providing significant advancements in longevity research.

Author of this paper? Send a correction.